• Exchange: Copenhagen
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech


352.700 DKK 1.400 0.40%

As of 11:01:58 ET on 12/19/2014.

Snapshot for Genmab A/S (GEN)

Open: 360.000 Day's Range: 347.600 - 365.000 Volume: 249,377
Previous Close: 354.100 52wk Range: 180.100 - 365.000 1-Yr Rtn: +58.52%

Stock Chart for GEN

No chart data available.
  • GEN:DC 352.700
  • 1D
  • 1M
  • 1Y
Interactive GEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GEN

Current P/E Ratio (ttm) 65.9252
Estimated P/E(12/2014) 85.0905
Relative P/E vs. KFX 3.2548
Earnings Per Share (DKK) (ttm) 5.3500
Est. EPS (DKK) (12/2014) 4.1450
Est. PEG Ratio 0.9362
Market Cap (M DKK) 20,092.41
Shares Outstanding (M) 56.97
30 Day Average Volume 215,535
Price/Book (mrq) 10.3647
Price/Sale (ttm) 22.5759
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/02/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GEN

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GEN

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil